Mendus B.V.
Previously recorded as Dcprime B.V. (to 2023)
When these terms end
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,470,789 | Method for inducing and accelerating cells In force · USPTO record | In force | USPTO record | |
| US 11,027,001 | Therapeutic cancer vaccines derived from a novel dendritic cell line In force · USPTO record | In force | USPTO record | |
| US 10,064,923 | Therapeutic cancer vaccines derived from a novel dendritic cell line In force · USPTO record | In force | USPTO record | |
| US 11,071,778 | Combination product for use in tumor vaccination In force · USPTO record | In force | USPTO record | |
| US 11,052,144 | Methods of tumor vaccination In force · USPTO record | In force | USPTO record | |
| US 12,091,681 | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy In force · USPTO record | In force | USPTO record | |
| US 12,364,758 | Use of leukemia-derived cells in ovarian cancer vaccines In force · USPTO record | In force | USPTO record | |
| US 12,397,055 | Methods of tumor vaccination In force · USPTO record | In force | USPTO record |
Sources and methods
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 1 no status recorded
Showing 1 to 4 of 4, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/804,310 | Ex Vivo Use of Modified Cells of Leukemic Origin for Enhancing the Efficacy of Adoptive Cell Therapy | Aug 14, 2024 | Pending |
| 18/499,357 | Prognostic Biomarkers for Cancer Relapse Vaccination and the Use Thereof | Nov 1, 2023 | Abandoned |
| 18/197,670 | Use of Leukemia-Derived Cells for Enhancing Natural Killer (NK) Cell Therapy | May 15, 2023 | Pending |
| 18/119,487 | Mar 9, 2023 | No status recorded |